We use cookies to give you the best possible experience on our website. By continuing to browse this site, you give consent for cookies to be used. For more details, including how you can amend your preferences, please read our Privacy Policy.

The HOT-HMV Study1: 51% reduction in risk of hospital readmission or death in hypercapnic COPD patients treated with home non-invasive ventilation and oxygen therapy.

HOT-HMV is the first multi-centre, open label, parallel-group, randomised controlled trial to show that home mechanical ventilation (HMV) combined with home oxygen therapy (HOT) significantly reduces the risk of hospital readmission or death in severe COPD patients after an acute COPD exacerbation requiring non-invasive ventilation.

Watch the study video
Watch an interview with
Prof. Nicholas Hart at ATS 2017
"The trial results could potentially change clinical practice and improve the way we manage our sickest COPD patients."

Prof. Nicholas Hart and Dr Patrick Murphy, who led the HOT-HMV trial from St Thomas' Hospital in London

Key findings of HOT-HMV

A 51% reduction in the risk of hospital readmission or death in the HOT-HMV arm compared to the HOT arm.

The absolute risk reduction at 12 months was 17%, translating to a need to treat 6 patients to avoid one hospital readmission or death in 12 months.

74% reduction in the risk of hospital readmission in the first 28 days after randomisation with two-thirds fewer events observed in this period.

In addition to the positive effect on time to first readmission or death*, further analysis showed that the exacerbation rate was reduced by 34% in the HOT-HMV arm.
*Median time to first event

High pressure ventilation effectively reduced CO2 levels and therapy was well tolerated as shown by results on quality of life and compliance.

HOT-HMV at ERS
ResMed Symposium Videos

From the European Respiratory Society (ERS) Congress, watch leading investigators from the HOT-HMV trial discussing the study results and their implications in clinical practice.

Home Non-Invasive Ventilation for patients with severe COPD

Prof Nicholas Hart

ERS 2017 – Evening Symposium, Milan, IT 11/09/2017

Home NIV in COPD: from screening to patient follow up, available tools and perspectives

Prof Jean-Louis Pepin

ERS 2017 – Evening Symposium, Milan, IT 11/09/2017

The importance of activity for COPD patients: clinical evidence and solutions to support it

Prof Dr Klaus Kenn

ERS 2017 – Evening Symposium, Milan, IT 11/09/2017

Panel Question & Answer

All

ERS 2017 – Evening Symposium, Milan, IT 11/09/2017

HOT-HMV: Study objectives, methodology and results

Dr Patrick Murphy

ERS 2016 Evening Symposium, London, UK 06/09/2016

Lessons learned from the HOT-HMV trial: What are the clinical implications?

Prof. Nicholas Hart

ERS 2016 Evening Symposium, London, UK 06/09/2016

Home NIV for COPD – where are we now with the evidence

Prof. Michael Dreher

ERS 2016 Evening Symposium, London, UK 06/09/2016

HOT-HMV study: Panel discussion and Q&A

Panelists: Dr Patrick Murphy, Prof. Nicholas Hart, Prof. Michael Dreher, Dr David White & Dr Holger Whoehrle

ERS 2016 Evening Symposium, London, UK 06/09/2016

ResMed in COPD

By listening to the needs of healthcare professionals, patients and the wider COPD care community, we are committed to researching, designing, manufacturing and supporting easy to use, low burden, integrated solutions to help you meet the different needs of individual COPD patients at different stages of the disease continuum.

References

1. P. Murphy et al., Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation. A Randomized Clinical Trial, JAMA. Published online May 21, 2017. doi:10.1001/jama.2017.4451.